Viagra will endure, EU patent loss a mere dent
This article was originally published in Scrip
Executive Summary
Viagra may have lost its patent in significant markets in Europe last week, but the treatment for erectile dysfunction is not about to flop out of the market. Experts forecast that the impact of the patent expiry will barely dent Pfizer's figures this year, and that it can be trusted to drive sales for the company for many years to come.